<DOC>
	<DOCNO>NCT00982878</DOCNO>
	<brief_summary>The purpose study describe Central Nervous System exposure maraviroc HIV-1 infected subject receive stable antiretroviral regimen , include maraviroc , steady state .</brief_summary>
	<brief_title>The Maraviroc Central Nervous System ( CNS ) Study</brief_title>
	<detailed_description>15 HIV-1 infected subject currently receive stable antiretroviral therapy recruit . At study entry , within 14 day screen procedure , subject commence maraviroc dose 150 mg twice daily . For rest study period antiretroviral therapy comprise : - Truvada™ one tablet daily 0900 - Kaletra™ two tablet twice daily 0900 2100 - maraviroc 150 mg twice daily 0900 2100 Subjects attend regular clinic visit study treatment phase . On day 15 , subject attend unit morning prior usual dosing time . Blood drawn ass plasma maraviroc concentration pre dose pre lumbar puncture . A lumbar puncture perform standard aseptic technique asses CSF maraviroc concentration routine CSF parameter . On completion study visit , subject cease maraviroc , continue usual antiretroviral regimen attend follow visit 10 day later .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infect male female sign informed consent plasma HIV RNA &lt; 50 copies/mL screen least one occasion last 3 month currently receive stable antiretroviral regimen comprise : tenofovir 245 mg daily emtricitabine 200 mg daily boost protease inhibitor previous protease inhibitor resistance document HIV1 genotypic resistance test Between 18 65 year age , inclusive subject good health upon medical history , physical exam , laboratory test Female subject heterosexually active childbearing potential ( i.e. , surgically sterile least two year post menopausal ) must practice contraception follow screen completion study include 30 day follow last dose study drug : barrier contraceptive ( condom , diaphragm spermicide ) IUD PLUS barrier contraceptive Female subject childbearing potential must negative pregnancy test . Male subject heterosexually active must use two form barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse , screen completion study include 30 day follow last dose study drug . Have serologic evidence active HBV infection evidence negative hepatitis B surface antigen serologic evidence hepatitis C virus infection HCV antibody HCV PCR . Have screen laboratory result ( haematology , chemistry , urinalysis ) fall within normal range central laboratory 's reference range unless result determine Investigator clinical significance current alcohol abuse drug dependence active opportunistic infection significant comorbidities include dementia current prohibit concomitant medication ( list section 4.1.4 ) Have body mass index ( BMI ) &gt; 32 Contraindication lumbar puncture examination . Such : Existing neurological disease Bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>treatment experience</keyword>
</DOC>